Clinical Biofluid Assays for Prostate Cancer

Area of Science:

• Oncology
• Biomarker Discovery
• Clinical Diagnostics

Background:

• Prostate cancer (PCa) is a prevalent malignancy with significant mortality, partly due to limitations in current diagnostic methods.
• The Prostate-Specific Antigen (PSA) test, while widely used, suffers from low specificity, leading to overdiagnosis and overtreatment.
• Tumor heterogeneity and invasiveness of biopsies complicate accurate PCa diagnosis and management.

Purpose of the Study:

• To review currently available clinical biofluid assays for prostate cancer (PCa).
• To discuss the advantages of liquid biopsies over traditional tissue-based tests.
• To explore emerging biomarkers for improved PCa detection and classification.

Main Methods:

• Review of existing literature on clinical biofluid assays for PCa.
• Discussion of FDA- and CLIA-approved blood and urine-based tests.
• Brief overview of promising, non-clinical biofluid marker candidates (e.g., DNA methylation, micro-RNAs).

Main Results:

• Newer blood tests (4K, PHI) and urine tests (PCA3, ExoDX, MiPS, SelectMDx) demonstrate higher specificity than traditional PSA testing.
• Liquid biopsies provide a less invasive alternative to tissue biopsies, better reflecting tumor heterogeneity.
• Several promising biofluid markers are under investigation for future clinical application.

Conclusions:

• Clinical biofluid assays, including blood and urine tests, offer improved diagnostic accuracy for PCa.
• Liquid biopsies represent a significant advancement, providing minimally invasive options for patients.
• A combination of multiple biomarkers and imaging is envisioned as the future standard for PCa management.